NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 68

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

MO 02120 31821

Licensee

1. Capital Region Medical Center
   Nuclear Medicine Department
2. 1125 Madison
   P.O. Box 1128
   Jefferson City, MO 65102

In accordance with letters dated **December 29, 2009, and January 29, 2010,**

3. License number 24-12699-01 is amended in its entirety to read as follows:

4. Expiration date June 30, 2015

5. Docket No. 030-02375
   Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed 1 curie of iodine-131)
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed Sources (Theragenics Corporation I-Seed Model 125.S06, Bard Brachytherapy Inc. Model STM 125-1; Theragenics Corporation Model 200; 3M Health Physics Services Model 6711; BEBIG Gmbh Model I25.S06; Best Industries Model Nos. 2301 and 2335; Implant Sciences Corp., Model 3500; International Brachytherapy, Inc. Model Nos. Intersource 1251L and 1032P; IsoAid, LLc Model IAI--125A; Mills Biopharmaceuticals, Inc. Model Nos. 125SL and 125SH; North American Scientific, Model Nos. Med 3631 and 3633.)	D. 2 curies of palladium-103, 2 curies of iodine-125, 4 curies total.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-12699-01

Docket or Reference Number
030-02375

Amendment No. 68

9. Authorized use:

   A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

   B. Any imaging and localization study permitted by 10 CFR 35.200.

   C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

   D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 1125 Madison, Jefferson City, Missouri.

11. The Radiation Safety Officer for this license is Kenneth L. Andrews, M.S., DABR.

12. Licensed material is only authorized for use by, or under the supervision of:

   A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

   B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
S. J. Westgate, M.D.	10 CFR 35.400.
Conrad Balcer, D.O.	10 CFR 35.100 and 35.200.
Mark Phillip Bryer, M.D.	10 CFR 35.300 and 35.400.
William L. Schlegel, D.O.	10 CFR 35.100 and 35.200.
Rodney Adkison, D.O.	10 CFR 35.100, 35.200 and 35.300.
Joseph M. Bean, M.D.	10 CFR 35.300 and 35.400.
James Russell Allen, M.D.	10 CFR 35.300 and 35.400.
Patrick J. Morello, M.D.	10 CFR 35.100 and 35.200.
Matthew Hrastich, D.O.	10 CFR 35.100 and 35.200.
Patricia O. MacFarlane, M.D.	10 CFR 35.100 and 35.200.
Mitchell T. Godbee, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries)
Raleigh F. Jonson, III, M.D.	**10 CFR 35.100 and 35.200.**

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-12699-01

Docket or Reference Number
030-02375

Amendment No. 68

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated December 6, 2004; and

    B. Facsimile letters dated May 26, 2005, June 6 and 7, 2005, March 8, 2006, and **February 17, 2010.**

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAR 03 2010

By Toye L. Simmons
Toye L. Simmons
Materials Licensing Branch
Region III